German drugmaker Grünenthal has named Maren Thurow as its new vice president and head of global communications, stepping into ...

A week after US President Donald Trump signed an executive order to bring back the Most Favored Nation (MFN) idea he ...

German vaccine pioneer BioNTech (Nasdaq: BNTX) today revealed that its UK subsidiary has signed a grant agreement with the UK ...

Marking International Clinical Trials Day, we bring you a special Q&A with Andrea Manfrin, Deputy Director of Clinical Trials ...

A new frontier into advancing treatments for children and adults with bone marrow failure, leukemia and other blood disorders ...

Shares in Prime Medicine, a US biotech seeking to develop one-time curative genetic therapies, closed 16% lower Monday.

Anti–interleukin five (IL-5) biologics such as mepolizumab and benralizumab have shown significant efficacy in reducing ...

German drugmaker Boehringer Ingelheim has released full Phase III results for its experimental lung disease drug ...

Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved UK pharma major GSK’s (LSE: GSK) Blenrep (belantamab ...

Swiss gene-editing specialist CRISPR Therapeutics (Nasdaq: CRSP) and San Diego, USA-based Sirius Therapeutics, which is ...

Cambridge, USA-based Apnimed today announced positive top-line results from its pivotal Phase III SynAIRgy clinical trial evaluating the efficacy and safety of its lead candidate AD109 (aroxybutynin 2 ...

Australia’s digital health sector is poised for steady expansion, with the market forecast to grow at a compound annual growth rate of around 8% through 2034, according to research from data and ...